2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 784

IgG4+ Plasmablasts Are A Novel Biomarker In IgG4-Related Disease
Abstract Number: 809

IgM Rheumatoid Factor As a Potentiator Of Anti-Citrullinated Protein Antibody Mediated Inflammation In Rheumatoid Arthritis
Abstract Number: 2822

IKKε Deficiency Prolongs Neutrophil Survival Paradoxically Prolonging Inflammation In The Absence Of a Type I Interferon Response
Abstract Number: 1637

IKZF1 Modulates PP2Ac Expression Through An Intronic Binding Site
Abstract Number: 2503

IL-17+ CD8+ T Cells Are Enriched In The Joints Of Patients With Psoriatic Arthritis and Correlate With Markers Of Disease Activity and Joint Damage Progression
Abstract Number: 2713

IL-21 Inhibited Follicular Regulatory T Cells To Promote Autoreactive Germinal Center Development In Autoimmune BXD2 Mice
Abstract Number: 634

IL-21/IL-21R Interaction On Lymphocyte Subsets From Lupus Patients
Abstract Number: 1289

IL-6 Is Required For Th1- and Th17- Mediated Arthritis
Abstract Number: 1855

IL-6 Promotes Systemic Bone Loss Via Upregulation Of S1PR2 In Osteoclast Precursors In a Mouse Collagen-Induced Arthritis Model
Abstract Number: 1823

IL-6 Suppresses Osteoblast Differentiation Through The SHP2/MEK2 and SHP2/Akt2 Pathways In Vitro
Abstract Number: 915

IL-6R Inhibition Reduces Activation Of Different Peripheral Memory B Cell Subsets In RA
Abstract Number: 1763

IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Abstract Number: 667

IL6 and CCL2 Co-Regulate Fibroblast Dependent Trans-Endothelial Migration Of Mononuclear Cells and Fibrotic Response In Scleroderma
Abstract Number: 1941

Imaging Atherosclerotic Plaque Inflammation In RA: Methodology and Initial Findings In a Single Centre Cohort
Abstract Number: 1826

Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].